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https://doi.org/10.1016/j.celrep.2021.108981SUMMARYDespite the central role of chromosomal context in gene transcription, human noncoding DNA variants are
generally studied outside of their genomic location. This limits our understanding of disease-causing regulatory
variants. INS promoter mutations cause recessive neonatal diabetes.We show that all INS promoter point mu-
tations in 60 patients disrupt a CC dinucleotide, whereas none affect other elements important for episomal
promoter function. To model CC mutations, we humanized an 3.1-kb region of the mouse Ins2 gene. This
recapitulated developmental chromatin states and cell-specific transcription. A CC mutant allele, however,
abrogated active chromatin formation during pancreas development. A search for transcription factors acting
through this element revealed that another neonatal diabetes gene product, GLIS3, has a pioneer-like ability to
derepress INS chromatin, which is hampered by the CCmutation. Our in vivo analysis, therefore, connects two
human genetic defects in an essential mechanism for developmental activation of the INS gene.INTRODUCTION
Most sequence variants underlying Mendelian diseases affect
coding sequences, although several patients are known to har-
bor causal cis-regulatory mutations (Benko et al., 2009; Garin
et al., 2010; Hansen et al., 2002; Lettice et al., 2003; Weedon
et al., 2014). This number is expected to rise asmillions of human
genomes are sequenced and the field learns to discriminate
pathogenic noncodingmutations from a vast number of inconse-
quential variants (Chong et al., 2015; Huang et al., 2017; Kowal-
ski et al., 2019; Ward and Kellis, 2012). In polygenic diseases,
common and rare cis-regulatory variants play a central role in
the genetic susceptibility (Cowper-Sal lari et al., 2012; Maurano
et al., 2012; Pasquali et al., 2014).
Despite the relevance of cis-regulatory variants, they have
been largely studied outside their chromosomal context. Current
experimental models usually test noncoding variants with
episomal DNA constructs, ectopically located transgenes, or
in vitro protein-DNA interaction assays. The extent to whichThis is an open access article under the CC BY-Nthese models reflect the true impact of cis-regulatory variants
is unknown. Expression quantitative trait loci can provide in-
sights into which genes are affected by regulatory variants in
their native genome context yet often fail to distinguish causal
from linked variants. It is now also possible to directly edit muta-
tions in stem cells and differentiate them in vitro, but this does not
always allow modeling the mutational impact in relevant devel-
opmental or physiological in vivo contexts. There is a need,
therefore, to develop complementary tools that facilitate under-
standing of the in vivo impact of noncoding variants.
One approach to address this need is to engineer human
genomic sequences in mice. Several examples of human knock-
ins in the mouse genome have been created to model human
protein-coding mutations (Zhu et al., 2019). One study success-
fully edited a 5-bp noncoding sequence in mice to model a com-
mon human regulatory variant (Pashos et al., 2017). However,
the extent to which mice can be used to study human cis-
regulatory mutations in more-extended orthologous genomic
contexts is poorly explored.Cell Reports 35, 108981, April 13, 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Location of INS promoter mutations
The top panel is a schematic of the human INS 50 flanking sequence, showing
approximate locations of established cis-regulatory sequences based on
published mutational analyses of episomal sequences. The bottom panel
shows a zoomed-in sequence that contains previously characterized MAFA,
NEUROD1, and PDX1-bound cis-elements (C1, E1, and A1, respectively), as
well as the CC element, with a graph that depicts the location of all INS pro-
moter recessive mutations from our analysis. Each dot represents a patient,
and the color represents the genotype. All single-base-pair mutations are
located in the CC element, including a distinct 24-bp deletion that disrupts
MAFA and NEUROD1 binding sites.
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major challenges, because the consequence of mutations that
disrupt transcription factor-DNA interactions can be influenced
by essential combinatorial interactions with nearby transcription
factor binding sites or by the existence of redundant binding
sites (Biggin, 2011; Heinz et al., 2013; Junion et al., 2012).
Unlike coding sequences, which are often highly conserved,
noncoding DNA sequences can maintain functions despite
substantial evolutionary turnover, and conserved noncoding se-
quences can acquire divergent functions (Khoueiry et al., 2017;
Villar et al., 2015). It is thus difficult to predict pathological
consequences of human cis-regulatory mutations from
mouse models unless the broader sequence context has been
humanized.
We have now examined a cis-regulatory mutation in the INS
gene that causes diabetes mellitus. A subset of patients with
neonatal diabetes harbors recessive loss-of-function coding or
promoter mutations in INS, encoding for insulin (Garin et al.,
2010). Single-nucleotide mutations of the INS promoter pub-
lished so far are located in a CC dinucleotide 331 bp upstream
of the INS start codon (Bonnefond et al., 2011; Deeb et al.,
2016; Demirbilek et al., 2015; Garin et al., 2010). Functional
studies in tumoral b cells using episomal luciferase assays
showed that c.-331C > G, the most common of these mutations,
causes partial disruption of INS promoter activity (Garin et al.,
2010). However, decades of work have shown that artificial mu-
tations in various other elements of the INS 50 flanking region that
disrupt binding by transcription factors, such asMAFA, PDX1, or
NEUROD1, also lead to reduced transcriptional activity in
episomal assays (Docherty et al., 2005; German et al., 1995;
Le Lay and Stein, 2006; Melloul et al., 2002; Odagiri et al.,
1996). This raises the question of whether the CC element is spe-
cifically vulnerable due to an essential role in the in vivo regula-
tion of the INS gene that cannot be examined in episomal assays.
In this study, we establish the selectivity of CC element muta-
tions in an extended cohort of patients. We humanized a large
noncoding region of the mouse Ins2 gene and used a mutant
version of this model to show that the c.-331C > G mutation dis-
rupts active chromatin formation during pancreas development.
We then linked the CC element to GLIS3, a zinc finger transcrip-
tion factor that also carries neonatal diabetes mutations, as well
as type 1 and type 2 diabetes risk variants (Barrett et al., 2009;
Dupuis et al., 2010; Senée et al., 2006). GLIS3, one of several
transcription factors known to regulate the insulin gene (Kang
et al., 2009; Yang et al., 2009), showed a singular capacity to
create INS gene active chromatin in non-pancreatic cells, and
this was inhibited in the CC mutant. This in vivo analysis of two
regulatory defects has therefore revealed a pioneering mecha-
nism of the human INS gene. These insights are relevant to the
mechanisms of diabetes and for regenerative strategies that
aim to activate the INS gene in non-pancreatic cells.
RESULTS
Human genetics establishes a unique role of the INS
promoter CC element
To further define the importance of the INS promoter CC
element, we re-examined the selectivity of mutations in a large2 Cell Reports 35, 108981, April 13, 2021cohort of previously published (n = 19) and unpublished (n =
41) patients with diabetes caused by recessive INS promoter
mutations. This showed that, among 60 patients from 44
families, all single-base-pair mutations located 50 of the tran-
scriptional start site resided in the CC element. This included
42 patients with c.-331C > G mutations (40 homozygous; two
compounds heterozygous), two with c.-332C > G mutations
(one homozygous; another compound heterozygous), and 13
with c.-331C > A mutations (12 homozygous; one compound
heterozygous with a c.-331C deletion; Figure 1; Table S1). This
newly described c.-331C single-base-pair deletion is interesting,
because it strongly favors a loss- rather than gain-of-function
mechanism for CCmutations. The only other pathogenic INS up-
streammutation was a larger homozygous deletion that disrupts
MAFA and NEUROD1 binding sites, which was observed in four
patients from two families. Most patients had characteristic clin-
ical features of insulin-deficient neonatal diabetes, with low birth
Figure 2. Generation of HIPKI and HIPKI-C331G mouse alleles
A rectangle with dotted lines in the top two panels depicts the 3.1-kb human
sequence located between the human TH and INS genes (including INS 50
untranslated transcribed sequences), which was cloned into a targeting vec-
tor. This targeting vector contained the 3.1-kb human INS upstream region
followed by Ins2-IRES-GFP, which includes mouse Ins2 exons and intron and
an IRES, GFP, and Ins2 30 UTR and was flanked by mouse Ins2 homology
arms. Targeted replacement of the indicated mouse Ins2 sequence with this
human upstream INS sequence followed by Ins2-IRES-GFPwas carried out by
homologous recombination. The same process was used to create two allelic
versions carrying the normal human INS sequence or the c.-331C > G muta-
tion. A neomycin cassette flanked by LoxP sites was excised in vivo and is
omitted for simplicity. The sequence of the neomycin-excised targeted allele is
provided in File S1.
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were diagnosed outside the neonatal period and 12 (including
both patients with -332 mutations) showed transient neonatal
diabetes (Table S1). No associated clinical abnormalities were
consistently noted in this patient series. These extended human
genetic findings, therefore, establish that the CC dinucleotide
sequence of the INS promoter is unusually sensitive to muta-
tions, suggesting a singular function of this cis-regulatory
element.
Generation of a human cis-regulatory mutation mouse
model
To study the function of the CC element in vivo, we modeled the
c.-331C > G mutation in a humanized sequence context. Wegenerated mice in which homologous recombination was used
to replace the endogenous 3.17-kb mouse genomic region con-
taining the Ins2 gene and its upstream regions with a human INS
upstream DNA fragment. This genomic region showed high-
sequence conservation to the mouse counterpart in an 350-
bp region upstream of INS TSS and another 500-bp region
downstream of the TH gene but contained intervening se-
quences lacking identifiable orthology with the mouse genome,
including a primate-specific variable number tandem repeat re-
gion previously reported to influence INS transcription (Kennedy
et al., 1995; Figure S1A). The knocked in allele thus contained (1)
this 3.10-kb upstream region of human INS, including a tran-
scribed INS 50 untranslated sequence; (2) mouse Ins2 exon1,
intron, and exon 2; and (3) an internal ribosome entry site
(IRES) followed by green fluorescent protein (GFP) sequence
(Figure 2). The resulting transcript was thus translated into two
proteins: mouse preproinsulin-2 and GFP. In parallel, we gener-
ated a mouse model harboring the same humanized sequence
and the INS c.-331C > G single point mutation (Figure 2). We
named mice carrying the two human INS upstream knockin al-
leles HIPKI and HIPKI-C331G.
Homozygous HIPKI and HIPKI-C331G mice were born at
expected Mendelian ratios and appeared healthy without overt
hyperglycemia (Figure S1B), consistent with the fact that HIP
knockin mice retained an intact copy of Ins1, a retroposed
mouse gene that also encodes insulin (Duvillié et al., 1997; Ler-
oux et al., 2001).
HIPKI recapitulates, and HIPKI-C331G abrogates, cell-
specific INS transcription
To determine whether the human INS 50 flanking region inserted
into its orthologous mouse chromosomal context was able to
drive b-cell-specific expression in HIPKI mice, we used dual
immunofluorescence analysis of GFP and islet hormones in tis-
sues from newborn mice (postnatal day 1 [P1]–P3). This showed
that GFP expression was restricted to insulin-positive pancreatic
islet core b cells of HIPKI mice, whereas it was not detected in
mantle glucagon- or somatostatin-positive islet cells or sur-
rounding exocrine cells (Figures 3A and 3B). Moreover, GFP
fluorescence was readily detected in live islets isolated from
3- to 5-month-old HIPKI mice (Figure 3C). Ins2-IRES-GFP
transcript was also restricted to islets across a panel of mouse
tissues (Figure S1C).
In sharp contrast to HIPKI islets, HIPKI-C331G islets showed no
detectable GFP fluorescence or immunoreactivity (Figures 3A–
3C). Thus, Ins2-IRES-GFP expression in HIPKI mice recapitulates
expected b-cell-specific patterns of insulin expression, whereas
the HIPKI-C331G mutation disrupts this expression pattern.
To further assess the function of human INS flanking
regions, we measured Ins2 mRNA in islets isolated from HIPKI
and HIPKI-C331G mice. Quantitative RT-PCR analysis revealed
Ins2 mRNA in islets isolated from both control C57BL/6 and
HIPKI mice, but not in HIPKI-C331G mouse (Figure 3D), thus con-
firming that the c.-331C > G single point mutation abrogates
transcriptional activity of the humanized INS/Ins2 locus in
mice. We note, however, that Ins2 transcripts in HIPKI islets,
which form part of the larger Ins2-IRES-GFP transcript, were




Figure 3. HIPKI recapitulates and HIPKI-C331G abrogates b cell-spe-
cific Ins2 expression
(A) Immunofluorescence imaging of insulin, glucagon, and GFP, showing se-
lective GFP expression in HIPKI insulin-positive core islet cells, but not in the
surrounding glucagon islet mantle, or in extra-islet exocrine cells. In contrast,
no GFP expression is detected in HIPKI-C331G islet cells.
(B) Immunofluorescence imaging of glucagon, somatostatin, and GFP,
showing lack of GFP expression in somatostatin or glucagon-positive cells.
(C) Bright-field and fluorescence imaging of islets isolated from HIPKI and
HIPKI-C331G mice.
(D) Quantitative PCR analysis of Ins2 and Ins1mRNAs in pancreatic islets from
3- to 5-month-old C57BL/6 (n = 4), HIPKI (n = 6), and HIPKI-C331G (n = 6) mice.
Values were normalized to Actb mRNA. ***p < 0.0001 (Student’s t test).
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scription and 14-fold reduced stability of the Ins2-IRES-GFP
transcript, as compared to the intact Ins2 mRNA from C57BL/6
islets (Figures S1D and S1E).
Further analysis revealed normal levels of Ins1, Pdx1, Glis3,
NeuroD1, MafA, Glut2, and Gck mRNAs in HIPKI and HIPKI-C331G
islets, suggesting that humanization of regulatory sequences in
the mouse Ins2 locus did not impact these key pancreatic b cell
identity markers (Figures 3C and S1F).
Mice with homozygous null Ins2 mutations display mild tran-
sient hyperglycemia (Duvillié et al., 1997; Leroux et al., 2001).
Consistently, HIPKI-C331G mice, which were Ins2-deficient,
showed mildly increased glycemia (119[32] versus 145[24] mg/
dL; mean [IQR]; Student’s t test p = 0.0031; Figure S1A).4 Cell Reports 35, 108981, April 13, 2021These findings indicate that an3-kb human INS upstream re-
gion can replace its mouse orthologous region and still direct
cell-specific transcription in mouse b cells. Furthermore, they
show that the human INS c.-331C > G point mutation abrogates
the function of this humanized region, consistent with the severe
phenotype observed in humans with neonatal diabetes.
HIPKI, but not HIPKI-C331G, islets mirror human islet INS
chromatin
Nucleosomes that flank promoters of transcriptionally active
genes are typically enriched in trimethylated histone H3 lysine
4 (H3K4me3) and acetylated histone H3 lysine 27 (H3K27ac),
and this was expectedly also observed in the human INS pro-
moter in human islets (Morán et al., 2012; Pasquali et al., 2014;
Figure S2). We thus examined these histone modifications at
the INS promoter in HIPKI and HIPKI-C331G adult mouse islets
by chromatin immunoprecipitation (ChIP) assays. The INS prox-
imal promoter showed enriched H3K4me3 and H3K27ac in adult
HIPKI mouse islets (Figures 4A–4C). By contrast, HIPKI-C331G is-
lets showed 5-fold and 7-fold lower signals (Student’s t test;
p < 0.001; Figures 4B and 4C). HIPKI-C331G islets also showed
markedly reduced INS promoter chromatin accessibility as
measured by formaldehyde-assisted isolation of regulatory ele-
ments (FAIRE) (Figure 4D) and reduced binding of PDX1, an islet
transcription factor that binds to multiple sites in the INS pro-
moter (Figure 4E). These findings, therefore, demonstrate that
the c.-331C > G point mutation does not only prevent transcrip-
tional activity conferred by the human INS 50 flanking region but
also the formation of accessible active chromatin and thereby
occupancy by a key INS gene transcription factor.
Activation of humanized INS locus during development
We next used HIPKI and HIPKI-C331G models to assess how the
c.-331C > G mutation influences chromatin activation at the
INS gene during pancreas development. As a reference, we
analyzed ChIP sequencing (ChIP-seq) maps of H3K4me1 and
H3K4me3 histone modifications in human fetal pancreas at Car-
negie stage 23 (Cebola et al., 2015), which precedes INS gene
activation, and compared them with analogous maps from adult
human islets (Morán et al., 2012; Pasquali et al., 2014). In the hu-
man fetal pancreas, we observed that the histone modification
H3K4me1 demarcated a broad region that encompasses the
TH and INS genes as well as downstream regions, without
detectable H3K4me3, a histone modification associated with
active promoters (Figure 5A). This combination, H3K4me1
enrichment and absence of H3K4me3, has been described in
genomic regions that are poised for gene activation (Creyghton
et al., 2010) and is consistent with the virtual absence of INS tran-
scription in the early fetal pancreas. In adult human islets, by
contrast, H3K4me1 in the INS locus was largely replaced with
H3K4me3, in keeping with active INS transcription (Figure 5A).
We next examined whether the chromatin environment that
precedes transcriptional activation of the INS locus is recapitu-
lated in HIPKI embryos. As in human fetal pancreas, we observed
deposition of H3K4me1 in the humanized INS flanking regions in
HIPKI embryonic day 12.5 (E12.5) mouse fetal pancreas (Fig-
ure 5B). Ins2 mRNA was expectedly not detected above back-




Figure 4. HIPKI recapitulates and HIPKI-
C331G abrogates formation of active chro-
matin at the INS locus
(A) Schematic showing approximate primer loca-
tions for ChIP assays. INSCC primers encompass
the CC element.
(B–D) ChIP quantification of H3K4me3, H3K27ac,
and FAIRE accessibility at the humanized INS lo-
cus and control regions in HIPKI or HIPKI-C331G
adult mouse islets. The Actb promoter was used
as a positive control, and a gene desert lacking
active histonemodifications in islets was used as a
negative control. ChIP and FAIRE DNA were ex-
pressed as a percentage of the total input DNA. n =
3 independent experiments.
(E) ChIP for the transcription factor PDX1 in HIPKI
or HIPKI-C331G adult mouse islets at a known
PDX1-bound enhancer near Pdx1 as a positive
control. Data are expressed as a percentage of
input DNA. n = 3 independent experiments. Error
bars indicate SEM; asterisks indicate Student’s t
test p values (*p < 0.05; **p < 0.001; ***p < 0.0001).
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(Figure 5B), indicating that the humanized INS sequences reca-
pitulate poised chromatin preceding gene activity, and this is not
impeded by the c.-331C > G mutation.
By contrast, the c.-331C > G mutation prevented the tran-
scriptional activation of the humanized locus at early stages of
b cell differentiation. Thus, Ins2 mRNA was detectable in HIPKI
E15.5 fetal pancreas, but it was undetectable in HIPKI-C331G em-
bryos (Figure 5C), whereas Ins1 mRNA was readily detected in
both HIPKI and HIPKI-C331G E15.5 pancreas (Figure 5C). Thus,
mice carrying humanized regulatory regions in the Ins2 locus
can recapitulate salient developmental features of the chromatin
landscape of the human INS locus and show that, although the
c.-331C > G mutation does not affect INS chromatin poising, it
disrupts activation of promoter chromatin in differentiated cells.
GLIS3-dependent activation of the INS gene is
prevented by c.-331C > G
We next sought to identify factors whose DNA binding activity is
influenced by the c.-331C > G mutation. We performed stable
isotope labeling by amino acids in cell culture (SILAC) experi-
ments and identified four zinc finger transcription factors (MAZ,
ZFP37, KLF13, and KLF16) that showed decreased in vitro bind-
ing to the c.-331C > G mutation and additionally selected 5 zinc
finger transcription factors expressed in human islets that were
predicted to show differential binding based on in silico and/or
literature analysis (Figure S3A). Of these 9 candidate transcrip-
tion factors, GLIS3, which was previously shown to bind to thiselement in vitro (Kang et al., 2009),
induced significant luciferase activity in
a human insulin promoter episomal
construct, and the c.-331C > G mutation
suppressed this effect (Student’s t test
p = 0.02; Figure 6A). Systematic DNA
binding site selection studies predict
that the C > G mutation impairs GLIS3binding (Beak et al., 2008), and this was confirmed with electro-
mobility shift assays (Figure S3B). These findings, therefore,
indicated that the c.-331C > G mutation disrupts GLIS3 in vitro
binding to the CC element as well as activation of an episomal
INS promoter.
Recently, GLIS3 was shown to bind in vivo to the Ins2 pro-
moter, and pancreatic inactivation of Glis3 in adult mice specif-
ically depletes Ins2 mRNA in islet cells (Scoville et al., 2019;
Yang et al., 2013). To test whether GLIS3 is a direct in vivo regu-
lator of the human INS gene, we performed ChIP-seq of GLIS3 in
human islets. This showed 746 high-confidence binding sites,
which displayed marked enrichment of canonical GLIS3 binding
sequences, including a de novomotif matching the INS promoter
CC element and a specific binding site in the INS promoter (Fig-
ures 6B and S4A; Table S2). Additional GLIS3-bound regions
were observed in genes known to be important for islet cells,
including PDX1,MAFA,CREB1, and DLL1 (Figure S4B). Further-
more, transduction of two independent short hairpin RNAs
(shRNAs) that reduced GLIS3 mRNA in human EndoCb-H1 b
cells led to 2-fold lower INS mRNA levels (Student’s t test p <
0.05; Figure S4C). This provided in vivo evidence that GLIS3 is
a direct regulator of the human INS gene.
To understand GLIS3-mediated regulation of INS locus chro-
matin, we assessed the ability of GLIS3 to activate INS in three
immortalized non-pancreatic human cell lines in which the INS
gene is repressed. Combinations of islet cell transcription factors,
such as PDX1, MAFA, and NEUROG3 or NEUROD1, have been




Figure 5. Developmental activation of INS
promoter chromatin during development
(A) H3K4me1 and H3K4me3 profiles at the INS lo-
cus showing H3K4me1, but not H3K4me3,
enrichment in human fetal pancreas (Carnegie
stage 23; Cebola et al., 2015) across the INS region
and H3K4me3, but not H3K4me1, enrichment in
adult human islets (Morán et al., 2012; Pasquali
et al., 2014).
(B) Top: approximate location of oligonucleotides
for ChIP assays. Bottom: ChIP H3K4me1 enrich-
ments in pancreas from HIPKI or HIPKI-C331G E12.5
embryos are shown. n = 2 independent experi-
ments from pools of 8–12 embryos. Data are ex-
pressed as a percentage of input DNA.
(C) Quantitative PCR analysis for Ins2 and Ins1
mRNA from HIPKI or HIPKI-C331G in E12.5 and E15.5
embryonic pancreas or E15.5 liver (n = 3). Error bars
indicate SEM; asterisks indicate Student’s t test p
values; ***p < 0.0001.
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that PDX1, MAFA, and NEUROD1 directly bind and regulate the
insulin gene promoter in various species (Le Lay and Stein,
2006; Zhao et al., 2005).We found that expression of various com-
binations of such transcription factors failed to elicit major
changes in INS mRNA in cell lines from distant lineages, namely
HEK293T, MCF7, or SW480 cells (Figures 6C and S5A). By
contrast, co-transfection of these factors with GLIS3 led to
ectopic activation of the endogenous INS gene (Figures 6C and
S5A). Other candidate transcription factors that were predicted
to bind to the CC element failed to activate INS in the presence
of PDX1 and NEUROD1 (Figure S5A). Microarray analysis of
HEK293T cells transfected with GLIS3, PDX1, NEUROD1, and
MAFA showed that INSwas themost highly induced gene relative
to cells that were only transfected with PDX1, MAFA, and
NEUROD1 (Figure S5B). These results indicate that GLIS3 has a
specific ability to activate the INS gene in cell lines fromdistant lin-
eages, which requires other INS promoter-binding transcription
factors that do not elicit this effect on their own.
To further understand this unique effect of GLIS3 on the INS
gene, we examined chromatin accessibility using FAIRE. Misex-
pression of GLIS3, PDX1, and NEUROD1 created accessible
chromatin at the endogenous INS gene in HEK293T cells,6 Cell Reports 35, 108981, April 13, 2021whereas this was not elicited by PDX1
and NEUROD1 alone (Figure 6D). This ef-
fect was direct, as ChIP experiments
showed that transfected GLIS3 was bound
to the INS promoter (Figure S5C). Thus,
GLIS3 has a singular ability to bind and
activate the INS promoter in repressed
chromatin cellular environments.
Because GLIS3 activation of episomal
INS promoter constructs was impaired
by the c.-331C > G mutation, we next
tested whether the GLIS3-dependent
chromatin pioneering function was also
mediated by the CC element.We thus pre-pared fibroblasts fromHIPKI andHIPKI-C331G embryos. Given that
other islet transcription factors are required for the GLIS3 effect,
we transduced HIPKI and HIPKI-C331G mouse embryonic
fibroblasts with PDX1, NEUROD1, MAFA, and GLIS3. This com-
bination of transcription factors activated transcription from the
humanized locus in HIP fibroblasts, whereas the effect was in-
hibited by the c.-331C > G mutation (Figure 6E).
These findings, therefore, indicate that GLIS3 has a distinct
pioneering function in the activation of human INS in an endog-
enous chromosomal context and indicate that c.-331C > G mu-
tation impairs this function.
DISCUSSION
We have examined the in vivo consequences of two gene-regu-
latory defects that cause diabetes mellitus. We studied an
extended cohort of patients with neonatal diabetes and provide
firm human genetic evidence that the CC element of the human
INS gene is selectively vulnerable to loss-of-function mutations.
We humanized a large genomic regulatory region in mice and
demonstrated that a neonatal diabetes point mutation in this
element disrupts an essential pioneering step in the activation
of the human INS gene. We further demonstrate that GLIS3,
Figure 6. GLIS3 activates the endogenous
INS gene and requires an intact CC element
(A) Transfection of candidate transcription factors
or PDX1 as a positive control, along with INS pro-
moter (wild-type or c.-331C > G) luciferase re-
porter plasmids in ENDOCb-H1 cells. Statistical
comparisons correspond to GLIS3 versus empty
expression vectors, both with a wild-type reporter
plasmid, or for hGLIS3 vector, the wild-type versus
c.-331C > G reporter plasmid.
(B) ChIP-seq shows GLIS3 binding to the INS
promoter (arrow) in human islets.
(C) GLIS3 activates INS in heterologous cell types.
HEK293T, MCF7, or SW480 cells were transfected
with plasmids encoding indicated transcription
factors or left untreated (unt). INS mRNA was
calculated as INS toGAPDHmRNA ratios3 1,000.
Significance was calculated relative to untreated
samples in 3 independent experiments.
(D) FAIRE assessment of accessible chromatin in
transfected HEK293T cells. FAIRE DNA was
quantified by PCR and expressed as percentage of
input DNA and fold enrichment over untreated
cells. Statistical significance was calculated rela-
tive to untreated samples (n = 3 independent ex-
periments). Expectedly, signal from NANOG and
GAPDH did not change.
(E) GLIS3-dependent activation of INS in fibro-
blasts obtained from HIPKI (n = 7) and HIPKI-C331G
(n = 10) embryos. Fibroblasts were transduced
with mouse GLIS3, MAFA, PDX1, and NEUROD1
lentivirus, and RNAwas analyzed after 2 days. Two
independent experiments were performed with
cells from 7HIPKI and 10 HIPKI-C331G embryos from
two litters. Error bars are SEM; asterisks are Stu-
dent’s t test; *p < 0.05; **p < 0.001; ***p < 0.0001.
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OPEN ACCESSwhich is also mutated in neonatal diabetes and harbors poly-
genic diabetes risk variants (Barrett et al., 2009; Dupuis et al.,
2010; Senée et al., 2006), has a unique role in the activation of
INS gene chromatin mediated by the CC element that is mutated
in neonatal diabetes. These results revealed cis and trans regu-
lators of an essential mechanism for developmental activation of
the endogenous INS gene.
Transcriptional regulatory DNA variants play a central role in
human disease (Miguel-Escalada et al., 2015), yet so far, most ef-
forts have investigated their function in experimental systems that
do not consider their in vivo impact (Cannon and Mohlke, 2018;
Corradin and Scacheri, 2014; Kircher et al., 2019). This is a major
limitation, because it is currently clear that gene regulation entails
a complex interplay between elements that are difficult to repro-
duce outside of an in vivo context, including chromatin structure,
epigenetic chemical modifications, or noncoding RNAs. Such
factors are highly dynamic throughout development and physio-
logical settings. Importantly, in vitro models cannot easilyexamine transcription factor-DNA interac-
tions that overcome repressed chromatin
states. Many transcription factors can
only bind recognition sequences in acces-
sible DNA, whereas a subset of transcrip-
tion factors have the ability to bind tonucleosomal-bound DNA and to reprogram silent chromatin
(Soufi et al., 2015; Zaret and Carroll, 2011). Such pioneer func-
tions play a major role in differentiation and cellular programming
and should thus be studied with in vivo approaches that recapit-
ulate salient genomic and chromatin contexts.
Previous work with a trans-species aneuploid model showed
that the human chromosome 21 can recapitulate human cell-
specific regulatory landscapes in mice (Wilson et al., 2008).
Our study has now shown that a human3.1-kb genomic region
could be integrated into an orthologous region of another
mammal and recapitulate stage- and cell-specific functions.
Importantly, we have modeled a human noncoding mutation in
an extended human regulatory sequence integrated in an orthol-
ogous mouse locus, thereby extended earlier models that intro-
duced human mutations in an orthologous mouse sequence
(Zhu et al., 2019). This in vivo strategy was essential to model
CC element mutations, because systematic in vitro binding
studies and episomal reporter assays have disclosed >16Cell Reports 35, 108981, April 13, 2021 7
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OPEN ACCESSbinding activities and functional elements in the human insulin
promoter that do not appear to harbor mutations that are patho-
genic in humans (Bonnefond et al., 2011; Docherty et al., 2005;
Garin et al., 2010; German et al., 1995; Melloul et al., 2002; Oda-
giri et al., 1996). Interestingly, a mutation of a 34-bp region that
contains the CC element in randomly integrated human INS
promoter transgenics did not significantly alter promoter activity
(Itier et al., 1996). Our humanizedmodel showed that the c.-331C
>Gmutation did not prevent INS chromatin priming in pre-differ-
entiated cells but disrupted H3K4 trimethylation, chromatin
accessibility, and transcription factor binding to the INS pro-
moter in differentiated b cells. This indicates that the CC element
acts as an essential seeding site for chromatin opening and tran-
scriptional activation of the INS promoter in b cell development.
It also shows that the essential function of this element can only
become fully apparent in a natural chromatinized environment,
such as that of human patients or mutant HIP mice.
Our studies also show that the Kr€uppel-like zinc finger protein
GLIS3 activates the human INS gene in vivo. This extends
studies showing that GLIS3 binds the mouse Ins2 promoter
in vivo and the human INS CC element in vitro (Kang et al.,
2009; ZeRuth et al., 2013). Furthermore, pancreatic Glis3-defi-
cient and Glis3+/ mice show severe abnormalities in insulin
expression (Scoville et al., 2019; Yang et al., 2013). Importantly,
our studies now show that GLIS3 has a selective ability among
known INS gene regulators to activate INS in cellular environ-
ments in which this locus is repressed. It is interesting to note
that GLIS1, a GLIS3 paralog, has a major impact on reprogram-
ming of pluripotent cells from somatic cells in the presence of
other pluripotency transcription factors (Maekawa et al., 2011),
and GLIS3 has a similar reprogramming function in some so-
matic cell lineages (Lee et al., 2017). It is therefore likely that
GLIS3 can derepress diverse target genes through combinatorial
interactions with cell-specific transcription factors. We have
further shown that the c.-331C > G mutation prevented GLIS3-
dependent activation of both episomal and integrated human
INS. These findings, therefore, provide a common mechanism
for genetic defects in GLIS3 and the INS CC element.
Our studies, therefore,uncover anunanticipatedprotagonismof
GLIS3 and theCCelement of the INS promoter to initiate an active
chromatin stateat thehuman INSgene.Ourfindingsare relevant to
understanding genetic mechanisms underlying diabetes, as well
as for efforts to use cis-acting sequences and transcription factors
to activate b cell genes for replacement therapies (Bakhti et al.,
2019; Ding et al., 2013; Zhou and Melton, 2018).STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:




B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Patients with monogenic diabetesCell Reports 35, 108981, April 13, 2021B Generation of HIPKI and HIPKI-C331G mice
B Human islets
B EndoCb-H1 cell line and culture




B Mouse islets and embryonic pancreas isolation and
processing
B FAIRE, ChIP and ChIP-Seq
B ChIP Buffers
B ChIP and FAIRE Library Preparation and sequencing
B ChIP and FAIRE data analysis
B Quantitative PCR analysis
B In silico motif analysis
B GLIS3 knockdown in EndoCb-H1 cells
B Luciferase assays
B Activation of endogenous INS in heterologous cell
types
B SILAC
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
celrep.2021.108981.
ACKNOWLEDGMENTS
This research was supported by the Birmingham Fellowship Programme, RD
Lawrence Fellowship (Diabetes UK, 20/0006136), and Academy of Medical
Sciences Springboard (SBF006\1140) to I.A. Other main funding sources (to
J.F.) are Ministerio de Ciencia e Innovación (BFU2014-54284-R and
RTI2018-095666-B-I00), Medical Research Council (MR/L02036X/1), a Well-
come Trust Senior Investigator Award (WT101033), European Research Coun-
cil Advanced Grant (789055), and FP6-LIFESCIHEALTH 518153. E.D.F. is a
Diabetes UK RD Lawrence Fellow (19/005971). A.T.H. and S.E. are the recip-
ients of a Wellcome Trust Senior Investigator award (WT098395/Z/12/Z), and
A.T.H. is employed as a core member of staff within the NIHR-funded Exeter
Clinical Research Facility and is an NIHR senior investigator. S.E.F. has a Sir
Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal So-
ciety (105636/Z/14/Z). Human islets for research were supported by the Juve-
nile Diabetes Research Foundation (2-RSC-2019-724-I-X). Work in CRG was
supported by the CERCA Programme, Generalitat de Catalunya, and Centro
de Excelencia Severo Ochoa (SEV-2015-0510). CRG acknowledges the
support of the Spanish Ministry of Science and Innovation to the
EMBL partnership. We thank the University of Barcelona School of Medicine
animal facility, Center of Genomic Regulation and Imperial College London
Genomics Units, and Larry Chan (Baylor College), Roland Stein (Vanderbilt
University), Anton Jetten (NIEHS, NIH, North Carolina), Doris Stoffers (Univer-
sity of Pennsylvania), Jochen Seufert (University of Freiburg), Marko Horb (Ma-
rine Biological Laboratory), Alpana Ray (University of Missouri), and Tatsuya
Tsurimi (Aichi Cancer Center, Ngoya, Japan) for generous gifts of valuable re-
agents and Kader Thiam (genOway) for overseeing the design of mouse
models. We thank Diego Balboa and Mirabai Cuenca for critical comments
on the manuscript. Graphical abstract drawings were by Yasemin Ezel with
clipart from Biorender.
AUTHOR CONTRIBUTIONS
I.A. and J.F. conceived and coordinated the study. I.A. performed cell-based
and computational studies and supervised mouse analysis. I.A. and M.A.M.
performed image analysis of mouse mutants and isolated islets. L.P. purified
Article
ll
OPEN ACCESShuman islets. V.G. maintained mouse colonies, G.M. performed SILAC exper-
iments, P.R. designed and created lentiviral vectors, and E.D.F., S.F., S.E., and
A.T.H. identified and studied patient mutations. I.A. and J.F. wrote the manu-
script with input from the remaining authors.
DECLARATION OF INTERESTS
P.R. is a shareholder and consultant for Endocells/Unicercell Biosolutions. The
other authors declare no competing interests.
Received: June 22, 2020
Revised: January 4, 2021
Accepted: March 23, 2021
Published: April 13, 2021
REFERENCES
Akerman, I., Tu, Z., Beucher, A., Rolando, D.M.Y., Sauty-Colace, C., Benazra,
M., Nakic, N., Yang, J., Wang, H., Pasquali, L., et al. (2017). Human pancreatic
b cell lncRNAs control cell-specific regulatory networks. Cell Metab. 25,
400–411.
Allen, H.L., Flanagan, S.E., Shaw-Smith, C., De Franco, E., Akerman, I., Cas-
well, R., Ferrer, J., Hattersley, A.T., and Ellard, S.; International Pancreatic
Agenesis Consortium (2011). GATA6 haploinsufficiency causes pancreatic
agenesis in humans. Nat. Genet. 44, 20–22.
Bailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren,
J., Li, W.W., and Noble, W.S. (2009). MEME SUITE: tools for motif discovery
and searching. Nucleic Acids Res. 37, W202–W208.
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Antibodies
GLIS3 Yang et al. (2011); L. Chan lab, Baylor
College of Medicine, Texas, USA
PMID 21786021
H3 mono methyl K4 Abcam ab8895
Histone H3 (acetyl K27) Abcam ab4729
H3 tri-methyl K4 Millipore 04-745
FLAG M2 (against GLIS3-FLAG) Sigma FLAG-M2 F3165
PDX1 BCBC Ab2027
Insulin Dako A0564
gunie pig anti-Glucagon MilliporeSigma 4031-01F
rabbit anti glucagon Dako A0565
Somatostatin Dako A0566
GFP R&D Systems AF4240
Immunoflourescence secondary antibodies Jackson immunoResearch Cy3, Cy5 and Alexa flour 488
Biological samples
Human Islets European Consortium on Islet
Transplantation (ECIT) AND Islets for Basic
Research Program supported by the
Juvenile Diabetes Research Foundation
https://ecit.dri-sanraffaele.org and
JDRF-program 2-RSC-2019-724-I-X
Chemicals, peptides, and recombinant proteins
Antibody diluent DAKO S3022
b-2-mercaptoethanol Sigma-Aldrich M3148-25ML
BSA Sigma-Aldrich A3059
BSA (for Endo-C culture only) Roche 10775835001
Calf Serum Sigma-Aldrich C8056-100ML
Collagenase Roche 11215809103
Diethylaminoethyl (DEAE) Sigma-Aldrich 67578-5G
DMEM Lonza be12-604f
DMEM 5.5mM Glucose Thermofisher Scientific 31885023
dsDNA BR assay kit Thermofisher Scientific Q32853
dsDNA HS assay kit Thermofisher Scientific Q32854
ECM gel Sigma-Aldrich E1270-10ML
EDTA Thermofisher Scientific AM9260G
Ethanol (immunoflourescence) Panreac Applichem, Spain 141086.1211
Ethanol Merck Millipore 108543







Histopaque 1077 Sigma-Aldrich 10771-500ml
Histopaque 1119 Sigma-Aldrich 11191-100ml
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REAGENT or RESOURCE SOURCE IDENTIFIER
L-Glutamine Cambrex BE17-605E
LiCl Sigma-Aldrich L9650-100G
Lipofectamine 2000 Invitrogen 11668-019
NEBNext Ultra DNA Library Prep Kit New England Biolabs E7370L




Normal donkey serum Jackson Immunoresearch 017-000-121
NP-40 substitute IGEPAL CA-630 Sigma-Aldrich I8896
Paraformaldehyde Agar Scientific R1026
PBS Sigma-Aldrich D-8537
Penicillin Lonza DE17-602E/ 17-745E
Phenol chloroform Sigma-Aldrich 77617-100ML
Power SYBR green mastermix Applied Biosystems 4368702
Protease inhibitor cocktail Roche 4693132001
Protein A Sepharose beads Ge Healthcare 17-0780-01
Protein G Sepharose beads Ge Healthcare 17-0618-01
Proteinase K Fermentas EO0492
Qiaquick columns QIAGEN 28106
RNase A Sigma-Aldrich R4875-100MG
RPMI 1640 medium Lonza BE12-702F
RPMI 1640 medium- without glucose Lonza BE12-752F
SDS Sigma-Aldrich 71736-500ML
SDS (ChIP) Invitrogen 15553-027
Sodium selenite Sigma-Aldrich S9133
Sodium-chloride Sigma-Aldrich S3014
Sodium-deoxycholate Sigma-Aldrich 30970-100G
Stratagene Site directed mutagenesis kit Stratagene (currently Thermofisher) A13282
Streptomycin Lonza DE17-602E/ 17-745E
Superscript III Reverse Transcriptase Invitrogen 18080093
SYBR green mastermix Applied Biosystems 4368708
TaqMan Probes Applied Biosystems costom
Transferrin Sigma-Aldrich T8158-100MG
TriPure reagent Invitrogen/ Roche 11667165001
Tris-HCL Life Technologies 15568-025
Trypsin-EDTA 0.05% GIBCO 25300062
Xylene PanReac/AppliChem 211769.1714
Critical commercial assays
Dual-LuciferaseReporter Assay System Promega E1960
Deposited data
GLIS3 ChIP-seq in human islets This paper GSE151405
H3K4me1, Human fetal pancrease Cebola et al., 2015 PMID: 25915126
H3K4me3, Human fetal pancrease Cebola et al., 2015 PMID:25915126
H3K4me1, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
H3K4me3, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
H3K27ac, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
PDX1, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
NKX6-1, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
FOXA2, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
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MAFB, Human donor-derived islet Pasquali et al., 2014 PMID:24413736
RNA-seq, Human donor-derived islet Akerman et al., 2017 PMID:28041957
Experimental models: cell lines
EndoCb-H1 Philippe Ravassard Laboratory N/A
Mouse embryonic fibroblasts (MEFs) Generated in this study N/A




C57BL/6 Charles River C57BL/6 (inbred)
HIPKI, HIPKI-C331G Generated in this study N/A
Oligonucleotides
Primers used in this study - Table S3 IDT N/A
Taqman Probe Ins1 Applied Biosystems Mm01259683_g1
Taqman Probe Ins2 Applied Biosystems Mm00731595_gh
Taqman Probe INS Applied Biosystems Hs02741908_m1
Taqman Probe Actb Applied Biosystems Mm00607939_s1
Taqman Probe ACTB Applied Biosystems Hs01060665_g1
Software and algorithms
FASTQC Babraham institute https://www.bioinformatics.babraham.ac.
uk/projects/fastqc/
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
MACS2 Zhang et al., 2008 https://github.com/macs3-project/MACS/
wiki/Install-macs2
Picard Suite Broad Institute https://broadinstitute.github.io/picard/
Rstudio RStudio Team (2020). RStudio:






Further information and requests for resources and reagents should be directed to and will be fulfilled by Ildem Akerman (i.akerman@
bham.ac.uk).
Materials availability
Materials generated in this study are available upon request from the lead contact.
Data and code availability
Accession number for GLIS3 ChIP-seq data is GEO: GSE151405 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE151405).
All code generated during this study is available upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients with monogenic diabetes
The study was conducted in accordance with the Declaration of Helsinki principles with informed parental consent given on behalf of
children. Patients reported in this study comprise all probands and family members with INS promoter homozygous or compound
heterozygous mutations sequenced in the Exeter Genomics laboratory, and 3 additional patients from the original joint description
of recessive INS mutations (DM1293.1, DM1293.2 and DM1265 in Table S1). The coding, flanking intronic regions and up to 450 bpe3 Cell Reports 35, 108981, April 13, 2021
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OPEN ACCESSupstream of the INS transcriptional start site (NM_000207.2) were analyzed by Sanger sequencing as previously described
(Garin et al., 2010). Clinical information was provided by the referring clinicians via a neonatal diabetes request form (available at
https://www.diabetesgenes.org) and from clinical notes.
Generation of HIPKI and HIPKI-C331G mice
Mouse experiments were conducted following procedures approved by the Ethical Committee of Animal Experimentation of the Uni-
versity of Barcelona. Targeted replacement of Ins2 with human INS 50 flanking sequences driving Ins2 and GFP was performed as
schematized in Figure 1 (genOway). The exact sequences of these regions are provided in File S1. In brief, targeting vectors were
generated with a 3.10 kb unmodified or mutated (c.C331G) 50 flanking INS region, Ins2 exon 1, intron, and exon 2, an IRES-GFP re-
porter cassette inserted in the 30 untranslated region of Ins2 exon 2, followed by a neomycin selection cassette flanked by loxP sites.
This construct was flanked by 5.3 kb and 1.8 kb C57BL/6J mouse homology arms. Targeting of this vector was carried out by ho-
mologous recombination in C57BL/6J embryonic stem cells, using a diphtheria toxon A cassette for negative selection. Recombi-
nants were verified by PCR screening and Southern blotting. Four suitable clones resulted, which were used for blastocyst injections
and generation of the HIP knock-in mouse strains.-This was followed by CRE-mediated excision of the neomycin cassette in vivo,
and again verified by PCR screening and Southern blotting. The sequence of the replaced region was verified by Sanger sequencing.
Oligonucleotides used for genotyping are shown in Table S3.
Human islets
Human pancreatic islets were obtained through the European Consortium on Islet Transplantation (ECIT), Islets for Basic Research
Program supported by the Juvenile Diabetes Research Foundation (program 2-RSC-2019-724-I-X). Pancreatic islets were isolated
from multiorgan donors without a history of glucose intolerance (Nano et al., 2015), shipped in culture medium and re-cultured at
37C in a humidified chamber with 5% CO2 in glucose-free RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin,
100 U/ml streptomycin and 11mM glucose for three days before analysis.
EndoCb-H1 cell line and culture
EndoCb-H1 cells were obtained fromP. Ravassard and cultured on plastic tissue culture vessels coatedwith 2 mg/ml Fibronectin and
1% extracellular matrix (ECM) (Sigma-Aldrich) and with the following media: DMEM containing 5.5 mM glucose (GIBCO), 2% bovine
serum albumin (BSA, Roche), 2 mM glutamine, 10 mM nicotinamide, 100 international units (U)/ml penicillin, 100 mg/ml streptomycin
(P/S), 50 mM b-2-mercaptoethanol, 5.5 mg/ml transferrin and 6.6 ng/ml sodium selenite at 37C in a humidified chamber with 5%CO2.
MEF, HEK293T, MCF7 and SW480 cultures and cell lines
Mouse embryonic fibroblasts (MEFs) were obtained from E15.5 HIPKI and HIPKI-C331G mouse embryos by clipping the tail tips and
culturing in media (DMEM (with glucose) supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 U/ml streptomycin at
37C in a humidified chamber with 5% CO2). HIPKI and HIPKI-C331G MEFs, HEK293T, MCF7 and SW480 cells were maintained in
DMEM (Lonza) and supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 U/ml streptomycin at 37C in a humidified
chamber with 5% CO2.
METHOD DETAILS
Immunofluorescence
Pancreases were processed for immunofluorescence as previously described (Maestro et al., 2003).Tissues were fixed in 4% para-
formaldehyde-PBS overnight at 4C with gentle rotation, then washed once in 20 mL cold PBS and embedded in parrafin. Paraffin
blocks were cut into 4 mm sections, deparaffinized with xylene by washing twice with a 15 minutes incubation. Xylene was removed
and the blocks were rehydrated through serial washes with 5 mL ethanol-water (100% Ethanol incubated for 5 min; 95% Ethanol
incubated for 5 min; 75% Ethanol incubated for 5 min; 100% Water incubated for 5 min) followed by an incubation with PBS for
5 min. Sections were blocked for 30 min at room temperature in antibody diluent (DAKO Corporation) with 3% normal serum-
PBS solution, using serum from the same species as the secondary antibody, and incubated overnight at 4Cwith primary antibodies
diluted in 100 mL of blocking buffer per section. Antibody dilutions used were: anti-insulin 1:200, anti somatostatin 1:200, rabbit anti
glucagon 1:200, guinea pig anti glucagon 1:1000, anti-GFP 1:200. We then incubated one hour at room temperature with secondary
antibodies also diluted in blocking buffer (100 ml/section) at the manufacturer’s recommended concentration (1:400 for fluoro-
chromesCy3 andCy5 and 1:800 for Alexa 488 fluorochrome). Images were acquired using Leica TSE confocal microscope for immu-
nofluorescence. Antibodies used are shown in Table S3.
Mouse islets and embryonic pancreas isolation and processing
Mouse islets were isolated using previously described protocols (Párrizas et al., 2001; van Arensbergen et al., 2010). C57BL/6, HIPKI
or HIPKI-C331G mice were anesthetized with urethane (15% solution, 1 ml/kg) and sacrificed. Pancreatic islets were isolated using the
following procedure: a cannula tube was inserted in the main pancreatic duct and the pancreas was inflated with Hanks’ balanced
salt solution (HBSS) buffer freshly added with 3U Collagenase P per ml. The pancreas was then removed, placed in a 15 mL falconCell Reports 35, 108981, April 13, 2021 e4
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OPEN ACCESStube and digested for 10 min at 37C in a water bath with constant, gentle agitation. The cell suspension was washed twice in 15 mL
cold HBSS–0.5% bovine serum albumin (HBSS-BSA), resuspended in 5 mL cold HBSS–BSA and gently passed through a needle
(0.8 mm diameter, 25 mm gauge). Islets were then washed by adding 10 mL of HBSS-BSA and sedimented for 3 minutes followed
by removal of 10mL from the top half of the solution (islets sediment to the bottom 5ml). Wash procedurewas repeated 3 times. Islets
were then sedimented at 1800 rpm (580 g) for 1 min at 4C and supernatant was removed. Islets were resuspended in 7mL of HBSS-
BSA and gently placed on top of 7 mL of histopaque mixture. Histopaque mixture is made freshly by mixing a 7:3 ratio of Histopaque
1077 and Histopaque 1119 (Sigma Aldrich). Histopaque mixture is heavier than HBSS-BSA and thus two distinct layers are formed.
The islets were collected at the interphase of the two layers through centrifugation at 2300 rpm (950 g) for 20min at room temperature
(Acceleration = 5, Deceleration = 0). The islet-enriched fraction was aspirated from the interface, washed three times in cold HBSS–
0.5% BSA, and further purified by handpicking under a stereomicroscope. Isolated islets were incubated in 11 mM glucose RPMI
1640medium, supplementedwith 10% fetal calf serum, 100U/ml penicillin, and 100U/ml streptomycin at 37C in a humidified cham-
ber with 5% CO2 for 48 hours after isolation. For ChIP experiments, mouse islets were immediately crosslinked with formaldehyde
after isolation and snap frozen at 80C until use.
For isolation of embryonic tissue, embryos from timed-pregnancies were placed in cold PBS and dissected under themicroscope.
Entire embryonic pancreas or liver tissue was removed and placed in 1 mL Tripure (Invitrogen) reagent for RNA harvest.
FAIRE, ChIP and ChIP-Seq
ChIP, ChIP-seq (Chromatin Immunoprecipitation and sequencing) and FAIRE (Formaldehyde-Assisted Isolation of Regulatory Ele-
ments) were performed essentially as previously published protocols (Gaulton et al., 2010; Nammo et al., 2011; Pasquali et al.,
2014). ChIP experiments using antibodies against H3K4me1 and H3K4me3 were performed on 250 mouse islet equivalents
(IEQ) per sample, while ChIP experiments using antibodies against PDX1 were performed on 400 mouse IEQ per sample. FAIRE
experiments were performed on 250 mouse IEQ. GLIS3 ChiP-seq experiments were performed with 3000 human IEQ, using a
previously described antibody (Yang et al., 2011; Table S3).
For ChIP, all cells were fixed in 1% formaldehyde-PBS for 10 minutes at room temperature with gentle agitation. Fixation was
stopped with addition of glycine to a final concentration of 125mM for 5 minutes with gentle agitation. Fixed cells were washed twice
in cold PBS. Fixed islets were then suspended in sonication buffer and sonicated using Bioruptor (Diagenode) to a length of 200–
1000 bp (12 minutes, 45sec ON, 45 s OFF). Samples were diluted with dilution buffer (1:4 ratio) to obtain 1% Triton X-100, 0.1%
SDS and 130 mM NaCl and were precleared with high speed spin (12,000 rcf., 5 minutes) followed by incubation with protein
A+G-Sepharose beads (1:1) (20 ml/sample) for 2 hours at 4C. Input DNA (1% of volume of sample) was collected and frozen. Sam-
ples were then subjected to immunoprecipitation with the indicated antibodies (1 mL of H3K4me1/3 and PDX1 and 3 mL of GLIS3
antibodies, Antibody sources are provided in Table S3) overnight at 4C with gentle rotation. Immune-complexes were collected
by incubation with protein A or G-Sepharose (15 ml/sample) for 2 h at 4C with gentle rotation. Beads were washed using standard
ChIP wash buffers (1x 1 mL low salt wash buffer, 1x 1 mL high salt wash buffer, 1x 1 mL LiCl buffer, 3x 1 mL TE buffer) and immu-
nocomplexes eluted with 300 mL elution buffer (incubation at room temperature for 15minutes with gentle agitation). Input and eluted
ChIP DNAs were subjected to reverse cross-linking (65C for 12 hours), RNase A (20 mg) and Proteinase K digestion (90 mg), and pu-
rification with Qiaquick columns (QIAGEN).
For FAIRE assays, sonicated chromatin was subjected to phenol chloroform extraction (2x) without immunoprecipitation and wash
steps62,63.
ChIP Buffers
Sonication Buffer: (2% Triton X-100, 0.5%SDS, 100mMNaCl, 1 mMEDTA,10mMTris-HCl pH 8.0 and 1x protease inhibitor cocktail
(freshly added)
Dilution Buffer: 0.75 % Triton X-100, 140 mM NaCl, 1 mM EDTA, 0.1% Na-deoxycholate, 50 mM HEPES pH8.0, 1x protease
inhibitor cocktail (freshly added)
Low Salt Wash Buffer: 20 mM Tris-HCl, pH 8.0, 140mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na Deoxycholate, 0.1% SDS,
1x protease inhibitor cocktail (freshly added)
High Salt Wash Buffer: 20 mM Tris-HCl, pH 8.0, 500mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Na Deoxycholate, 0.1% SDS,
1x protease inhibitor cocktail (freshly added)
LiCl Buffer: 20mM Tris-HCl (pH 8.0), 250mM LiCl, 1mM EDTA, 0.5% Na Deoxycholate, 0.5% NP-40 substitute (IGEPAL),
1x protease inhibitor cocktail (freshly added)
TE Buffer: 10mM Tris-HCl (pH 8.0), 1mM EDTA, 1x protease inhibitor cocktail (freshly added)
Elution Buffer: 10mM Tris-HCl (pH 8.0), 1mM EDTA, 1% SDS, 1x protease inhibitor cocktail (freshly
ChIP and FAIRE Library Preparation and sequencing
Sequencing and processing were performed as described (Pasquali et al., 2014). Input DNA samples were quantified with QUBIT
dsDNA BR assay kit (Q32853), and ChIP DNA samples were quantified with QUBIT dsDNA HS assay kit (Q32854). Quantitatione5 Cell Reports 35, 108981, April 13, 2021
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OPEN ACCESSwas performed using Qubit 2.0 fluorometer. ChIP-Seq DNA libraries were prepared from 5-10 ng of Input DNA or ChIP DNA using
NEBNext Ultra DNA Library Prep Kit for Illumina sequencing (New England BioLabs, # E7370L) by the Imperial College Genomics
Facility. Libraries were sequenced using Illumina HiSeq2500.
ChIP and FAIRE data analysis
Reads were subjected to quality control analysis using FastQC (v0.11.5) followed by trimming by the Picard suite (default options).
Trimmed reads were aligned to the human genome (hg19) using bowtie (Langmead and Salzberg, 2012) (v2.2.6, default options).
Peaks were called using MACS2 (Zhang et al., 2008) (v2.2.1, q-value cutoff 0.05, band width 300) as enrichment over ChIP Input
DNA. GLIS3-bound regions (peaks) are provided in Table S2.
References for new and previously reported human islet and fetal pancreas ChIP-seq datasets used in this study (Cebola et al.,
2015; Morán et al., 2012; Pasquali et al., 2014) are provided in Table S4.
Quantitative PCR analysis
RNA was isolated using TriPure reagent as described (Akerman et al., 2017) following manufacturer’s instructions. RNA quality was
ascertained with a 2100 Agilent Bioanalyzer (RIN > 8). Ins2, INS, ActB and Ins2 intronic transcripts were measured using TaqMan
(Applied Biosystems) probes, while other regions were quantified using oligonucleotide primers and SYBR green mastermix (Illu-
mina). cDNA synthesis was carried out using Superscript III (Invitrogen) and real-time PCR was performed with the ABI 7300 Real
Time PCR system using the Power SYBR Green reagent (Applied Biosystems). Serial dilutions of genomic DNA (5 data points)
were used to establish a standard curve. SDS software (Applied Biosystems) was used to generate quantitative values based on
the standard curve with arbitrary units. All mRNA levels were normalized to ActB or Hprt as indicated in Figure legends. Oligonucle-
otides and TaqMan probe sequences can be found in Table S3.
In silico motif analysis
To identify candidate transcription factors that bind the CC element, we performed in silico motif searches using the MEME suite
(Bailey et al., 2009) using the normal andmutated (c.331 C >G) sequences. Analysis of de novo and previously characterized position
weight matrixes (PWM) was performed with HOMER (v3.12) (Heinz et al., 2010) using peak summit coordinates and flags -size
50,50 -len 6,8,10,12.
GLIS3 knockdown in EndoCb-H1 cells
Lentiviral-mediated knockdown of GLIS3 in the human pancreatic b-cell line EndoCb-H1 was performed with two independent
shRNAs placed in artificial miRNAs as described in detail (Akerman et al., 2017). In brief, five non-targeting and two GLIS3-targeting
amiRNAs were designed using BLOCK-IT software (Invitrogen) and cloned into pTRIP-CMV gateway vectors as described (Akerman
et al., 2017). These were then used to produce lentiviruses (Scharfmann et al., 2014), which were transduced into the EndoC-bH1
cells. For knockdown experiments, cells were dissociated with trypsin (0.05%), washed twice with room temperature PBS. 105 cells
per well (24 wells) were incubated with lentivirus (60 ng of p24 capsid protein) and 10mg/ ml Diethylaminoethyl (DEAE) in 400 mL of
medium for 1 hour at 37C. Cells were harvested at 80 hours post-transduction, and RNA levels were assessed using real time
PCR. The efficiency of transduction was judged to be > 95%based onGFP expression. Oligonucleotides used for shRNAs are shown
in Table S3.
Luciferase assays
INS promoter activity was measured by transfection of a reporter plasmid: pSOUAPRL-251hINS-Luc (Roland Stein, Vanderbilt Uni-
versity), which contains 251 bp of human INS proximal promoter DNA located in front of the Firefly luciferase cDNA. The c.C331G
mutationwas introduced using site directedmutagenesis (Garin et al., 2010) using Stratagene site directedmutagenesis kit, following
manufacturer’s instructions. The presence of the mutation was verified by Sanger sequencing. The plasmids (0.5 mg/24 well) were
transfected into EndoCb-H1 with Lipofectamine 2000 at 4:1 luciferase:overexpression vector ratio as previously described (Allen
et al., 2011), followingmanufacturer’s instructions. We co-transfected a Renilla expressing construct (pGL4.75, 0.02 ng) as a normal-
izer to correct for differences in transfection efficiency. Expression vectors used in co-transfections are given in Table S3. Luciferase
activity was measured at 48 hours post- transfection using a luminometer (Promega Veritas Microplate luminometer) with the re-
agents of the Promega Dual-Luciferase Reporter Assay System.
Activation of endogenous INS in heterologous cell types
MEFs were transduced with lentiviral vectors, one encoding the transcription factors PDX1, NEUROD1 and MAFA in a polycistronic
transcript, and the other mouse GLIS3-DN155 (Beak et al., 2008; Table S3). Cells were harvested 48 hours post transduction and
subjected to quantitative PCR analysis. HEK293T, MCF7 and SW480 cells were transfected using Lipofectamine 2000, following
manufacturer’s instructions. We note that the omission of MAFA or substitution of NEUROD1 with NEUROG3 in such experiments
resulted in similar INS induction levels. For microarray hybridization experiments described in Figure S5, harvested RNA was hybrid-
ized to Gene ST 1.0 Affymetrix arrays and the data was analyzed on Affymetrix TAC (v1.0.24) software as described (Pasquali et al.,




We used Stable Isotope Labeling by Amino acids in Cell culture (SILAC) for mass spectrometry identification of proteins that specif-
ically bound to unmodified or mutated (c.C331G) double stranded oligonucleotides containing a 50 linker and PstI restriction site
(Table S3), exactly as described in detail (Mittler et al., 2009), using MIN6 immortalized mouse beta-cells (Miyazaki et al., 1990).
MIN6 cells were maintained in DMEM (4.5g/L Glucose), 15% fetal calf serum, 100 U/ml penicillin, 100 U/ml streptomycin at 37C
in a humidified chamber with 5% CO2) and 50 mM beta-mercaptoethanol. SILAC identified 4 proteins whose binding was affected
by the mutation: Krueppel-like factor 13 (UniProtKB/Swiss-Prot Q9Y2Y9), Krueppel-like factor 16 (UniProtKB/Swiss-Prot Q9BXK1),
MAZ (UniProtKB/TrEMBL Q8IUI2) and ZFP37 (UniProtKB/Swiss-Prot Q9Y6Q3).
QUANTIFICATION AND STATISTICAL ANALYSIS
Boxplots were drawn using Rstudio (v3.5). Line within the boxplot represents median, whereas the bounds of the box define the first
and third quartiles. Bottom and top of whiskers represent minimum and maximum numbers respectively for each boxplot. Dot plots
and bar plots were drawn using Excel. Where indicated, Student’s t test was used to calculate statistically significant differences
between samples.e7 Cell Reports 35, 108981, April 13, 2021
